Brainstorm Cell Therapeutics (NASDAQ:BCLI) Issues Earnings Results

Brainstorm Cell Therapeutics (NASDAQ:BCLI) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14), Yahoo Finance reports. During the same quarter in the prior year, the business earned ($0.19) earnings per share.

Brainstorm Cell Therapeutics Price Performance

NASDAQ:BCLI opened at $0.18 on Wednesday. The firm’s 50-day moving average price is $0.44 and its 200-day moving average price is $1.60. The company has a market capitalization of $7.96 million, a PE ratio of -0.25 and a beta of -0.24. Brainstorm Cell Therapeutics has a 1-year low of $0.13 and a 1-year high of $3.46.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. StockNews.com started coverage on shares of Brainstorm Cell Therapeutics in a research report on Sunday. They set a “hold” rating on the stock. Maxim Group lowered Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 28th.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

Hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its position in shares of Brainstorm Cell Therapeutics by 739.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 8,862 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 7,806 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Brainstorm Cell Therapeutics in the second quarter worth $33,000. XTX Topco Ltd bought a new position in shares of Brainstorm Cell Therapeutics during the first quarter valued at $40,000. Renaissance Technologies LLC purchased a new position in shares of Brainstorm Cell Therapeutics in the 2nd quarter worth about $47,000. Finally, Virtu Financial LLC bought a new position in Brainstorm Cell Therapeutics in the 2nd quarter worth about $57,000. Institutional investors own 20.97% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.